Urinary Vitamin C Loss in Diabetic Subjects
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT00071526
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 5000
- US sites recruiting
- 1
- Study start
- April 11, 2006
- Record last updated
- October 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Several studies have reported that diabetic subjects have lower plasma vitamin C concentrations than non-diabetic subjects. Although urinary vitamin C loss in diabetic subjects was reported to be increased in two studies, these are difficult to interpret due to lack of controlled vitamin C intake, inadequate sampling, lack of control subjects, or methodology uncertainties in vitamin C assay and sample processing. Consequently, it is unclear whether diabetic subjects truly have both low plasma and high urine vitamin C concentrations. We propose that low plasma vitamin C concentrations in diabetic subjects are due in part to inappropriate renal loss of vitamin C in these subjects but not in healthy controls. We will study nondiabetic controls and cohorts with diabetes. Vitamin C concentrations in plasma, RBCs, and urine will be measured in outpatients. In those willing to be admitted to the Clinical Center, we will measure vitamin C pharmacokinetics to determine the relative bioavailability for vitamin C in individuals with and without abnormal urinary loss of vitamin C (or renal leak). Single nucleotide polymorphisms (SNPs) will be determined in genomic DNA responsible for the two proteins mediating sodium dependent vitamin C transport, SVCT1 and SVCT2. We will also explore mechanisms underlying abnormal urinary vitamin C loss....
Conditions: Diabetes
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
- INCLUSION CRITERIA:
To be included in the study, study subjects should be:
- Aged 18-65 years.
- Either:
- Have no diagnosis of diabetes: "nondiabetic controls", or
- Have a diagnosis in their medical history of either Type 1 or Type 2 diabetes
EXCLUSION CRITERIA (for outpatient study, arm 1)
Exclusion criteria will include the following:
- Unable or unwilling to provide a signed and dated informed consent form
- Unable or unwilling to comply with study procedures and lifestyle considerations
EXCLUSION CRITERIA (for inpatient studies, arms 2 and 3)
Study participants interested in participating in Arms 2 and/or 3 will be excluded from this further participation if they meet any of the following:
- significant organ malfunction leading to clinical instability including liver disease, pulmonary disease, ischemic heart disease, heart failure, stroke, peripheral vascular disease, and anemia at investigator discretion
- other serious or chronic illness; history of serious or chronic illness; coronary artery disease, or peripheral vascular disease resulting in clinical instability
- pregnancy or lactation
- presence of other conditions which, in the judgment of the investigators, can influence vitamin C metabolism or vitamin C renal handling
Recruiting US locations
National Institutes of Health Clinical Center
Bethesda, MD 20892
Study contacts (from the official record)
- Razi S Berman, C.R.N.P. · (301) 827-5757 · razi.berman@nih.gov
- Ifechukwude C Ebenuwa, M.D. · (301) 435-6582 · ifechukwude.ebenuwa@nih.gov
Similar studies in Maryland
All diabetes studies in Maryland →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Brooklyn, MD + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1/Phase 2
Vasopressin and Pain Perception in the Brain
University of Maryland, Baltimore
- Location
- Baltimore, MD
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Silver Spring, MD + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Bowie, MD + 121 other US sites
- Eligibility basics
- Ages 55+